The sell-off in shares of Durect (DRRX) has accelerated meaningfully as the stock is now down...


The sell-off in shares of Durect (DRRX) has accelerated meaningfully as the stock is now down 37% premarket after Pfizer's Remoxy comments. Reminder: DRRX is entitled to royalties of between 6% and 11.5% of potential Remoxy net sales which some analysts have said could ultimately hit $1B if the drug reaches market. The impact for DRRX, which only had $53.1M in total revenue in 2012, really cannot be overstated. See SA contributor PropThink's recent analysis for more. (Also: PTIE crashes on PFE comments)

From other sites
Comments (1)
  • Red Acre Investments
    , contributor
    Comments (488) | Send Message
     
    $DRRX has Posidur under NDA review as well - $PTIE is worse off than $DRRX due to this news
    10 May 2013, 08:57 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs